<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:department>Blizard Institute of Cell and Molecular</gtr:department><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/251ADAA2-674C-4D0D-944F-5C6E42310B93"><gtr:id>251ADAA2-674C-4D0D-944F-5C6E42310B93</gtr:id><gtr:firstName>Inderjeet</gtr:firstName><gtr:surname>Dokal</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/BF607E33-5ED0-4A6D-85A8-CC1E8B7B1900"><gtr:id>BF607E33-5ED0-4A6D-85A8-CC1E8B7B1900</gtr:id><gtr:firstName>Thomas</gtr:firstName><gtr:surname>Vulliamy</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FK000292%2F1"><gtr:id>704E620A-5B7C-4177-BF70-88C2F68BFF2E</gtr:id><gtr:title>The genetic basis and pathophysiology of bone marrow failure syndromes</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/K000292/1</gtr:grantReference><gtr:abstractText>The bone marrow (BM) failure syndromes are a diverse group of life threatening disorders affecting children and adults. They are unified by the inability of the BM (the site of blood cell production) to make an adequate number of mature blood cells (red cells, white cells and platelets) and patients die prematurely from infection or bleeding if adequate treatment is not available. There are many different subtypes of BM failure. This includes the categories of dyskeratosis congenita (a severe inherited disorder in which many other systems of the body can be affected in addition to the blood system), idiopathic aplastic anaemia (the commonest type of BM failure whose cause remains unknown) and myelodysplasia (characterized by abnormalities in normal maturation of blood cells and where the underlying primary cause remains unknown). In approximately 40% of dyskeratosis congenita patients the genetic basis is unknown and in aplastic anaemia and myelodysplasia the primary cause remains unknown in over 80% of patients. 

The main aim of this research project is to determine the genetic basis and primary causes in the many uncharacterized cases of bone marrow failure. The experiments will involve undertaking genetic studies (including those based on the recently developed techniques of large scale gene sequencing so called next generation sequencing) in families with two or more affected cases with BM failure we have collected over the last 20 years. These studies will lead to the identification and characterization of new genes and cell pathways that are of fundamental importance. From the clinical perspective these studies will provide new diagnostic genetic tests and the possibility of developing new treatments that are highly desirable since prognosis remains unsatisfactory for many patients with bone marrow failure.</gtr:abstractText><gtr:technicalSummary>The bone marrow (BM) failure syndromes are a heterogeneous group (including those with the subtypes dyskeratosis congenita, aplastic anaemia and myelodysplasia) of life threatening disorders affecting children and adults. They are unified by the inability of the BM to make an adequate number of mature blood cells and patients die prematurely from infection or bleeding. For one of these syndromes, dyskeratosis congenita (DC), we hold a large unique registry, with samples stored from more than 370 families. In approximately 40% of these DC patients the genetic basis is unknown and in aplastic anaemia and myelodysplasia the primary pathology remains unknown in over 80% of cases. The main aim of the research is to determine the genetic basis and primary pathophysiology of the bone marrow failure syndromes dyskeratosis congenita, aplastic anaemia, and myelodysplasia. To facilitate this goal we will undertake genetic analysis (including those based on next generation sequencing) in families we have collected with two or more affected individuals with aplastic anaemia and/or myelodysplasia/leukaemia, but which do not meet the criteria of known bone marrow failure syndromes. Characterization of the familial forms of aplastic anaemia/myelodysplasia/leukaemia will lead to the identification of new genes and biological pathways that are likely to be important in the idiopathic forms of these disorders. Elucidation of the genetic basis will provide new diagnostic and therapeutic strategies that are highly desirable since treatment remains unsatisfactory for many patients with bone marrow failure.</gtr:technicalSummary><gtr:potentialImpactText>The potential beneficiaries of the research are:

i. Patients with bone marrow failure and their families 
This research can be expected to provide new diagnostic tests and in the long term potentially new therapies for patients with bone marrow failure. Over the three year period of the grant it is anticipated that several new bone marrow failure genes will be discovered, potentially 1-3 new genes/year. This will therefore be of considerable benefit to these patients as it will facilitate accurate diagnosis and appropriate management. It will also enable carrier testing for at risk relatives. This will include the identification of asymptomatic and pre-symptomatic carriers, as well as offering the possibility of excluding carrier status in prospective parents.

ii. Clinicians who treat patients with bone marrow failure 
Clinicians who look after patients with bone marrow failure will benefit from this research as further characterization of the genetic basis of these disorders will assist them in making prompt and accurate diagnosis thereby facilitating appropriate management. In the long term it could provide the basis for developing new treatments for this group of life threatening disorders. 

iii. The general public
Our group has liaised with the BBC and several other media outlets in the last two years regarding the importance of telomerase and telomeres in human health and disease. In the course of the proposed research we would expect to make at least one further programme related to our new research discoveries. This would help the general public obtain further insights into the genetic basis of bone marrow failure. It will also help them understand how such advances are important in developing new tests and treatments for this group of life threatening disorders.

iv. School children
Our group is situated in the Blizard Institute which houses the Centre of the Cell specifically established to engage with school children for the explanation and promotion of the types of scientific research that are conducted within our institute. It is the first centre of its kind in the world to be based within a working medical school research laboratory and can host up to 40 000 visitors each year. This gives us an excellent opportunity to engage school children in science including the research developments from this project. We believe this will have long term impact as it may go some way to nurture future scientists in the UK.</gtr:potentialImpactText><gtr:fund><gtr:end>2016-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2013-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>539723</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>The diagnosis and management of bone marrow failure</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>EAED8DAF-87C6-4D52-AA98-1E6B3C6CC97B</gtr:id><gtr:impact>The improve genetic diagnosis of bone marrow failure patients is enabling more appropriate clinical management. This includes guidelines on management of aplastic anaemia being published in the British Journal of Haematology (2016; 172: 187-207)</gtr:impact><gtr:outcomeId>58a6cd7815ace4.90482610</gtr:outcomeId><gtr:type>Citation in clinical reviews</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>D82249ED-525A-4A04-BF81-49BF5BEC7023</gtr:id><gtr:title>ERCC6L2 mutations link a distinct bone-marrow-failure syndrome to DNA repair and mitochondrial function.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3fdd3b0f754f7489fa3392bc468a824"><gtr:id>d3fdd3b0f754f7489fa3392bc468a824</gtr:id><gtr:otherNames>Tummala H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn><gtr:outcomeId>5450e1ae112198.28014263</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>42796028-F6F7-4253-A6F5-8A308F192C9A</gtr:id><gtr:title>Haematological recovery in dyskeratosis congenita patients treated with danazol.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6748198d73c0b7cf80253c70c80504d4"><gtr:id>6748198d73c0b7cf80253c70c80504d4</gtr:id><gtr:otherNames>Islam A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>dRA1md35Lip</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BA00B6E0-7178-4C7F-9841-4B9F29EFF2F1</gtr:id><gtr:title>Clinical utility gene card for: Dyskeratosis congenita - update 2015.</gtr:title><gtr:parentPublicationTitle>European journal of human genetics : EJHG</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/86e08524abe173d490ea818b63e33942"><gtr:id>86e08524abe173d490ea818b63e33942</gtr:id><gtr:otherNames>Dokal I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1018-4813</gtr:issn><gtr:outcomeId>56657a69cd4c78.81947331</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CEA0CADD-8BE7-489B-811D-F550B13BA0C0</gtr:id><gtr:title>DNAJC21 Mutations Link a Cancer-Prone Bone Marrow Failure Syndrome to Corruption in 60S Ribosome Subunit Maturation.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3fdd3b0f754f7489fa3392bc468a824"><gtr:id>d3fdd3b0f754f7489fa3392bc468a824</gtr:id><gtr:otherNames>Tummala H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn><gtr:outcomeId>585d6edb01ebb3.88920774</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E3071F6C-F1B7-4576-9221-F95C9AAE23A1</gtr:id><gtr:title>Triallelic and epigenetic-like inheritance in human disorders of telomerase.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/242186763069e3fb4e3515c20340feda"><gtr:id>242186763069e3fb4e3515c20340feda</gtr:id><gtr:otherNames>Collopy LC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>56657b3ae4dc53.20829387</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4E0D653C-44D1-427A-8409-A8219FEC4624</gtr:id><gtr:title>Targeted resequencing of 52 bone marrow failure genes in patients with aplastic anemia reveals an increased frequency of novel variants of unknown significance only in SLX4.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/242186763069e3fb4e3515c20340feda"><gtr:id>242186763069e3fb4e3515c20340feda</gtr:id><gtr:otherNames>Collopy LC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn><gtr:outcomeId>5450e293e33d89.50552685</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3728A3E6-3B04-40B7-9F17-0F98F0031F73</gtr:id><gtr:title>Constitutional mutations in RTEL1 cause severe dyskeratosis congenita.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5f781fb7b203b3fb7e3794e7d7ab43b5"><gtr:id>5f781fb7b203b3fb7e3794e7d7ab43b5</gtr:id><gtr:otherNames>Walne AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn><gtr:outcomeId>PoWa7REf2yg</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2FE9FA28-82C5-4F6D-A722-D0F12825FE32</gtr:id><gtr:title>Marked overlap of four genetic syndromes with dyskeratosis congenita confounds clinical diagnosis.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5f781fb7b203b3fb7e3794e7d7ab43b5"><gtr:id>5f781fb7b203b3fb7e3794e7d7ab43b5</gtr:id><gtr:otherNames>Walne AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn><gtr:outcomeId>58a6cac8102be7.63485474</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A5373BF6-8391-4E6B-9340-1D9AF922B00E</gtr:id><gtr:title>Germline heterozygous DDX41 variants in a subset of familial myelodysplasia and acute myeloid leukemia.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c42e8607d5db89f1270a6699ed4cb93f"><gtr:id>c42e8607d5db89f1270a6699ed4cb93f</gtr:id><gtr:otherNames>Cardoso SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>5a324751577ce1.80480343</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>589F6F19-EDBE-42C0-B218-30EEEF2C54CA</gtr:id><gtr:title>Poly(A)-specific ribonuclease deficiency impacts telomere biology and causes dyskeratosis congenita.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3fdd3b0f754f7489fa3392bc468a824"><gtr:id>d3fdd3b0f754f7489fa3392bc468a824</gtr:id><gtr:otherNames>Tummala H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>56657affe20043.74454354</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/K000292/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>939798CA-B6AE-4C12-9DCC-A0F88F84E6F3</gtr:id><gtr:percentage>34</gtr:percentage><gtr:text>Blood</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>78FE8F42-8AFB-48F8-8662-37D541AD95BF</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>Congenital Disorders</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>